While biomarker testing is currently predominantly carried out within centralized pathology laboratories, there is a significant scope for the decentralization of such assays through so-called point of care (POC) testing. For instance, POC testing could allow for on-site detection of infectious diseases or biosafety threats. The inherent capabilities of POC technologies to deliver rapid diagnostic data would also greatly impact on emergency medicine and assist in treatment decision in time-sensitive procedures (e.g. extent of surgical resection in solid tumours). Finally, reliable and cost-effective POC testing has the potential to dramatically improve routine healthcare monitoring, for instance for diseases associated to ageing (e.g. neurodegenerative diseases, cancer, chronic cardiovascular diseases).

To address the challenges of POC sensing, we are conducting research aimed at developing translational sensing platforms. These developments are based on improved understanding of the physical mechanisms underpinning solid-state biosensors and are focused on Field Effect Transistor and plasmonic sensing platforms.

A specific focus of our research aims at developing intraoperative sensing devices, i.e. technologies able to provide results within the time-frame of a surgery. An example of application is in the area of cancer staging and you can read more about recent developments here.











Leave a Reply